A setback in the development of GlaxoSmithKline plc's high profile vaccine candidate for respiratory syncytial virus (RSV) has intensified. The company announced on 28 February that rather than just pausing enrollment and vaccination in clinical trials evaluating the vaccine in pregnant women it is halting the trials due to a safety issue that has not been disclosed.
The studies impacted all involve pregnant women, including the Phase III GRACE trial evaluating the safety and efficacy of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?